HCV related chronic liver disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Age, over 20 years old 2) Male and female 3) Patients who has inslin resistance 4) Patients who has no HCC 5) Patients who obtained the consent
Exclusion criteria
Exclusion criteria: 1) Cirrotic patients with BCAA formulation while taking 2) Patients during interferon therapy in chronic hepatitis C, cirrhosis 3) Patients receiving medication for diabetes 4) Patients in the intake of dietary supplements containing the BCAA and zinc 5) Patients for branched-chain amino acids and zinc formulation, with a history of hypersensitivity 6) Pregnant woman and women who may possibly be pregnant, women in nursing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Improvement of insulin resistance 2) Reduction of oxidative stress | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Change of HCV-RNA 2) Improvement of loss of zinc 3) Improvement of BTR 4) Incidence of HCC 5) Occurrence of side effect | — |
Countries
Japan
Contacts
Yamaguchi Univercity Graduate School of Medicine Department of Gastroenterology and Hepatology